Burlington, Massachusetts, December 6, 2022 – MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has acquired Massachusetts-based Erbi Biosystems, a developer of the 2 ml micro-bioreactor platform technology, known as the “Breez™”. The deal strengthens MilliporeSigma’s upstream portfolio in therapeutic proteins by enabling scalable cell-based perfusion bioreactor processes from 2ml to 2000L with rapid lab-scale process development. It also offers future development opportunities in novel modality applications, including cell therapies. Financial terms were not disclosed.
You May Also Like
Erbi Biosystems Strengthens Executive Leadership Team with Appointment of Chief Scientific Officer
Travis FoeglerJune 1, 2022
NSF ERC CMaT Welcomes Erbi Biosystems as an Industry Member
Travis FoeglerApril 26, 2022
Innovative US company Erbi Biosystems joins AdBIOPRO as new industrial partner
Travis FoeglerMarch 23, 2022